The 31 references in paper O. Reshet'ko V., K. Lutsevich A., О. Решетько В., К. Луцевич А. (2018) “Фармакоэкономика как инструмент клинической фармакологии для оптимизации фармакотерапии (обзор) // Pharmacoeconomics as an instrument of clinical pharmacology for optimization of pharmacotherapy (review)” / spz:neicon:vedomostincesmp:y:2015:i:4:p:54-57

1
Ritter JM. Money makes the world go round: the pervasiveness of pharmacoeconomics. Br J Clin Pharmacol. 2008; 66: 755–7.
(check this in PDF content)
2
Drummond M. Pharmacoeconomics: friend or foe? Ann Rheum Dis 2006; 65 (Suppl. III): iii44–iii47.
(check this in PDF content)
3
Pang F. Design, analysis and presentation of multinational economic studies. The need for guidance. Pharmacoeconomics 2002; 20: 75–90.
(check this in PDF content)
4
Petrov VI. Pharmacoepidemiology and pharmacoeconomics in Russia: the status of the problems and prospects of development. Klinicheskie issledovanija lekarstv v Rossii 2002; (1): 8-10 (in Russian).
(check this in PDF content)
5
Edlin R, Round J, Hulme C, McCabe C. Cost effectiveness analysis and efficient use of the pharmaceutical budget: the key role of clinical pharmacologists. Br J Clin Pharmacol. 2010; 70: 350–355.
(check this in PDF content)
6
Mohan L, Kumari KM, Dikshit H, Biswas NR. Pharmacoeconomic exercise for undergraduate medical students. Int J Basic Clin Pharmacol. 2014; 3: 1099– 1100.
(check this in PDF content)
7
Kulkarni U, Deshmukh YA, Moghe VV, Rege N, Kate M. Introducing pharmacoeconomics (PE) in medical undergraduate curriculum. Afr J Pharm Pharmacol. 2010; 4: 27–30.
(check this in PDF content)
8
Babar ZU, Scahill S. Is there a role for pharmacoeconomics in developing countries? Pharmacoeconomics 2010; 28: 1069–74.
(check this in PDF content)
9
Singh J. International society for pharmacoeconomics and outcomes research. Indian J Pharmacol. 2006; 38: 376–7.
(check this in PDF content)
10
Lyles A. Recent trends in pharmacoeconomics: Needs and unmet needs. Eur J Pharm Sci 2008; 34: S7-S24.
(check this in PDF content)
11
Brazier J. Valuing health states for use in cost-effectiveness analysis. Pharmacoeconomics 2008; 26: 769–79. R E F E R E N C E S
(check this in PDF content)
12
Drummond M, Barbieri M, Cook J, Glick H, Lis J, Malik F, et al. Transferability of economic evaluations across jurisdictions: ISPOR good research practices task force report. Value Health 2009; (12): 409–18.
(check this in PDF content)
13
Bodrogi J, Kalo Z. Principles of pharmacoeconomics and their impact on strategic imperatives of pharmaceutical research and development. Br J Pharmacol. 2010; 159: 1367–73.
(check this in PDF content)
14
Honig PK, Lalonde R. The economics of drug development: a grim reality and a role for clinical pharmacology. Clin Pharmacol Ther. 2010; 87: 247–51.
(check this in PDF content)
15
Honig PK. Comparative effectiveness: The fourth hurdle in drug development and a role for clinical pharmacology. Clin Pharmacol Ther. 2011; 89: 151–6.
(check this in PDF content)
16
Krammer H. Pharmacoeconomic analyses – chance or 4th hurdle for innovative drugs. Wien Med Wochenschr 2006; 156: 606–11.
(check this in PDF content)
17
Grabowski H, Vernon J, DiMasi JA. Returns on research and development for 1990s new drug introductions. Pharmacoeconomics 2002; 20 (Suppl. 3): 11–29.
(check this in PDF content)
18
Robertson J, Lang D, Hill S. Use of pharmacoeconomics in prescribing research. Part 1: costs-moving beyond the acquisition price for drugs. J Clin Pharm Ther. 2003; 28: 73–9.
(check this in PDF content)
19
Newby D, Hill S. Use of pharmacoeconomics in prescribing research. Part 2: cost-minimization analysis – when are two therapies equal? J Clin Pharm Ther. 2003; 28: 145–50.
(check this in PDF content)
20
Lopert R, Lang DL, Hill S. Use of pharmacoeconomics in prescribing research. Part 3: Cost-effectiveness analysis – a technique for decision-making at the margin. J Clin Pharm Ther. 2003; 28: 243–9.
(check this in PDF content)
21
Brinsmead R, Hill S. Use of pharmacoeconomics in prescribing research. Part 4: is cost-utility analysis a useful tool? J Clin Pharm Ther. 2003; 28: 339–46.
(check this in PDF content)
22
McCabe C, Dixon S. Testing the validity of cost-effectiveness models. Pharmacoeconomics 2000; 17: 501–13.
(check this in PDF content)
23
Khanna D, Tsevat J. Health-related Quality of Life – an introduction. Am J Managed Care 2007; 13: S218-S223.
(check this in PDF content)
24
Vemer P, Rutten-van Molken MPMH. Largely ignored: the impact of the threshold value for a QALY on the importance of a transferability factor. Eur J Health Econ. 2011; 12: 397–404.
(check this in PDF content)
25
Hughes D. An agenda for UK clinical pharmacology. Pharmacoeconomics. Br J Clin Pharmacol. 2012; 73: 968–72.
(check this in PDF content)
26
Hughes D, Reynolds DJ. Pharmacoeconomics: principles and relevance to the activities of drug and therapeutics committees. Clin Med. 2009; 9: 490–2.
(check this in PDF content)
27
Rohilla A, Kumar A, Keshari R, et al. Pharmacoeconomics: An overview. International Journal of Research in Pharmacy and Chemistry 2013; 3: 64–8.
(check this in PDF content)
28
Waldman SA, Terzic A. Pharmacoeconomics in the era of individualized medicine. Clin Pharmacol Ther. 2008; 84: 179–82.
(check this in PDF content)
29
Iram M, Rani S, Hiremath R. Pharmacoeconomics: Need for the day. Indian J Pharm Pract. 2009; 2: 16–18.
(check this in PDF content)
30
Vegter S, Boersma C, Rozenbaum M, Wilffert B, Navis GJ, Postma MJ. Pharmacoeconomic evaluations of pharmacogenetic and genomic screening programmes: a systematic review on content and adherence to guidelines. Pharmacoeconomics 2008; 26: 569–87.
(check this in PDF content)
31
Petrov VI, Sabanov AV. Pharmacoeconomic studies in the Russian health care system. Klinicheskie issledovanija lekarstv v Rossii 2004; (1): 7 (in Russian). 12. Drummond M, Barbieri M, Cook J, Glick H, Lis J, Malik F, et al. Transferability of economic evaluations across jurisdictions: ISPOR good research practices task force report. Value Health 2009; (12): 409–18.
(check this in PDF content)